Sangamo Therapeutics Navigates Nasdaq Exit While Advancing Neurological Pipeline

Sangamo shifts to OTCQB after failing Nasdaq's $1 bid rule, while showcasing promising neurology data and seeking partnerships to secure funding.

Sangamo Therapeutics is charting a dual course this week, balancing a critical operational shift with scientific progress. The genomic specialist has been forced to move its stock trading to the OTCQB Venture Market after failing to meet Nasdaq’s minimum $1 bid price requirement, even as the company showcases promising data for its neurological programs at a major industry conference.

The delisting follows a prolonged period of share price weakness. Nasdaq rules mandate a minimum closing price of $1, and Sangamo could not sustain that threshold despite an extended compliance period that ran through late April 2026. Trading has now resumed under the familiar ticker SGMO on the less regulated OTC platform, though management has indicated it plans to appeal the decision. That hearing, however, will not pause the current suspension.

For investors, the transition to OTC trading brings tangible consequences. The market is known for thinner liquidity and wider bid-ask spreads, which can make buying and selling more costly. Institutional funds often face mandates requiring listings on major exchanges, meaning many may be forced to exit their positions. The company is working with an investment bank to identify strategic partners or alternative financing sources, with the Fabry disease program seen as a key asset to secure upfront payments.

On the scientific front, Sangamo presented data at the 29th Annual ASGCT Meeting that underscores its strategic pivot toward neurology. The company is developing ST-503, a therapy targeting chronic neuropathic pain through zinc finger repressors that regulate the Nav1.7 gene, which governs pain signal transmission. Crucially, this approach does not permanently alter DNA but instead suppresses gene activity at the molecular level, aiming for long-term relief. Clinical trial sites are already being activated.

A significant technical hurdle in neurological drug development is the blood-brain barrier, which blocks most therapeutics from reaching the central nervous system. Sangamo’s STAC-BBB capsule technology appears to overcome this obstacle after a simple intravenous infusion, delivering treatments directly to the brain. Partners are already leveraging this platform for research into Alzheimer’s and prion diseases.

The company is also refining its gene-editing toolkit, developing modular integrases designed to insert large DNA segments into cells with greater precision than conventional viral vectors. This could broaden the range of treatable conditions.

Sangamo is transforming itself into a clinical neurology specialist, though regulatory review of its Fabry disease therapy continues. The financial runway remains the critical constraint — without a timely partnership or capital injection, the company faces a real risk of insolvency. Management has pledged to disclose details of any definitive agreements once signed, but for now, the race is on to secure the resources needed to keep its pipeline alive.